GlaxoSmithKline LLC, operating as GSK, is a biopharmaceutical company headquartered in London, United Kingdom. It discovers, develops, manufactures, and commercializes medicines and vaccines with a focus on respiratory diseases, immunology and inflammation, oncology, HIV, and infectious diseases.
As of June 2026, GSK is in the process of acquiring Nuvalent for $10.6 billion to expand its oncology portfolio, including lung cancer drug candidates with FDA designations.
Tender offer launched at $124 per share; requires majority of Class A shares tendered and HSR clearance; no guaranteed delivery; offer set to expire July 14, 2026.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
